

Product datasheet for **TL312157V**

CXCR2 Human shRNA Lentiviral Particle (Locus ID 3579)

Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	CXCR2 Human shRNA Lentiviral Particle (Locus ID 3579)
Locus ID:	3579
Synonyms:	CD182; CDw128b; CMKAR2; IL8R2; IL8RA; IL8RB
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	CXCR2 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 ⁷ TU/ml.
RefSeq:	NM_001168298 , NM_001557 , NM_001557.1 , NM_001557.2 , NM_001557.3 , NM_001168298.1 , BC037961 , BC037961.1 , NM_001557.4 , NM_001168298.2
UniProt ID:	P25025
Summary:	<p>The protein encoded by this gene is a member of the G-protein-coupled receptor family. This protein is a receptor for interleukin 8 (IL8). It binds to IL8 with high affinity, and transduces the signal through a G-protein activated second messenger system. This receptor also binds to chemokine (C-X-C motif) ligand 1 (CXCL1/MGSA), a protein with melanoma growth stimulating activity, and has been shown to be a major component required for serum-dependent melanoma cell growth. This receptor mediates neutrophil migration to sites of inflammation. The angiogenic effects of IL8 in intestinal microvascular endothelial cells are found to be mediated by this receptor. Knockout studies in mice suggested that this receptor controls the positioning of oligodendrocyte precursors in developing spinal cord by arresting their migration. This gene, IL8RA, a gene encoding another high affinity IL8 receptor, as well as IL8RBP, a pseudogene of IL8RB, form a gene cluster in a region mapped to chromosome 2q33-q36. Alternatively spliced variants, encoding the same protein, have been identified. [provided by RefSeq, Nov 2009]</p>
shRNA Design:	<p>These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.</p>




[View online »](#)


**Performance
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.


For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).

Product images:


GFP signal was observed under microscope at 48 hours after transduction of TL312157A virus into HEK293 cells. TL312157A virus was prepared using lenti-shRNA TL312157A and [TR30037] packaging kit.



GFP signal was observed under microscope at 48 hours after transduction of TL312157B virus into HEK293 cells. TL312157B virus was prepared using lenti-shRNA TL312157B and [TR30037] packaging kit.



GFP signal was observed under microscope at 48 hours after transduction of [TL312157C] virus into HEK293 cells. [TL312157C] virus was prepared using lenti-shRNA [TL312157C] and [TR30037] packaging kit.



GFP signal was observed under microscope at 48 hours after transduction of [TL312157D] virus into HEK293 cells. [TL312157D] virus was prepared using lenti-shRNA [TL312157D] and [TR30037] packaging kit.